Market Place
Sourcing Support
Kineta Updates KVA12123 Phase 1/2 Data at SITC 2024
08 Nov 2024 //
GLOBENEWSWIRE
Kineta Completes Enrollment In VISTA-101 Ph 1 Study For Solid Tumors
08 Oct 2024 //
GLOBENEWSWIRE
Kineta, Inc Transitioning from Nasdaq to OTC Markets
19 Sep 2024 //
GLOBENEWSWIRE
Kineta Reopens VISTA-101 Trial For KVA12123 In Advanced Solid Tumors
19 Aug 2024 //
GLOBENEWSWIRE
Kineta Grants TuHURA Biosciences Rights To Its VISTA Blocking Antibody
08 Jul 2024 //
GLOBENEWSWIRE
Kineta Reports Q1 2024 Results, VISTA-101 Trial, Corporate Update
15 May 2024 //
GLOBENEWSWIRE
Kineta Reports Initial Clinical Response Data at AACR 2024
08 Apr 2024 //
GLOBENEWSWIRE
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
21 Mar 2024 //
GLOBENEWSWIRE
KVA12123 Clears Cohorts in Monotherapy in the Phase 1/2 VISTA-101 Trial
12 Mar 2024 //
GLOBENEWSWIRE
Kineta Announces Restructuring and Exploration of Strategic Alternatives
29 Feb 2024 //
GLOBENEWSWIRE
Kineta faces shutdown as private placement fails to show up
29 Feb 2024 //
FIERCE BIOTECH
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123
22 Feb 2024 //
GLOBENEWSWIRE
Kineta to Present at Upcoming Investor Conferences
14 Feb 2024 //
GLOBENEWSWIRE
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series
07 Feb 2024 //
GLOBENEWSWIRE
Kineta Provides Update on its Phase 1/2 VISTA-101 Clinical Trial of KVA12123
17 Jan 2024 //
GLOBENEWSWIRE
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
04 Jan 2024 //
GLOBENEWSWIRE
Kineta Publishes Data Demonstrating Potential of Anti-VISTA Antibody KVA12123
13 Dec 2023 //
GLOBENEWSWIRE
Kineta to Host KOL Event to Review Data from VISTA-101 Trial of KVA12123
28 Nov 2023 //
GLOBENEWSWIRE
Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit
09 Nov 2023 //
GLOBENEWSWIRE
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123
06 Nov 2023 //
GLOBENEWSWIRE
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody
03 Nov 2023 //
GLOBENEWSWIRE
Kineta Reports Third Quarter 2023 Financial Results
03 Nov 2023 //
GLOBENEWSWIRE
Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Trial of KVA12123
17 Oct 2023 //
GLOBENEWSWIRE
Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted
12 Oct 2023 //
GLOBENEWSWIRE
Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023
09 Oct 2023 //
GLOBENEWSWIRE
Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering
05 Oct 2023 //
GLOBENEWSWIRE
Kineta, Inc. Announces $3 Million Registered Direct Offering
04 Oct 2023 //
GLOBENEWSWIRE
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody
04 Oct 2023 //
GLOBENEWSWIRE
Kineta Announces Positive KVA12123 Monotherapy Safety
03 Oct 2023 //
GLOBENEWSWIRE
Kineta Announces Participation at October Investor Conferences
28 Sep 2023 //
GLOBENEWSWIRE
Kineta to Present Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR
25 Sep 2023 //
GLOBENEWSWIRE
Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression
18 Sep 2023 //
GLOBENEWSWIRE
Kineta to Participate in Upcoming Investor Conferences
31 Aug 2023 //
GLOBENEWSWIRE
Kineta Reports Q2 2023 Financial Results and Provides Corporate Update
11 Aug 2023 //
GLOBENEWSWIRE
Kineta to Receive $5 Million Milestone Payment from Merck
29 Jun 2023 //
GLOBENEWSWIRE
Kineta Expands BOD with Biotech Industry Leaders Kim Drapkin & Scott Dylla
28 Jun 2023 //
GLOBENEWSWIRE
Kineta Set to Join Russell Microcap Index
24 May 2023 //
GLOBENEWSWIRE
Kineta to Present at Jefferies Healthcare Conference
23 May 2023 //
GLOBENEWSWIRE
Kineta Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Kineta Announces Closing of $6 Million Registered Direct Offering
24 Apr 2023 //
GLOBENEWSWIRE
Kineta, Inc. Announces $6 Million Registered Direct Offering
20 Apr 2023 //
GLOBENEWSWIRE
Kineta Unveils New VISTA Biomarker Data and KVA12123 Ph1/2 Trial at AACR
17 Apr 2023 //
GLOBENEWSWIRE
Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123
12 Apr 2023 //
GLOBENEWSWIRE
Kineta to Present at 22nd Annual Needham Healthcare Conference
03 Apr 2023 //
GLOBENEWSWIRE
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
31 Mar 2023 //
GLOBENEWSWIRE
Kineta to Present VISTA Biomarker Data at AACR Annual Meeting 2023
22 Mar 2023 //
GLOBENEWSWIRE
Kineta to Present at the Oppenheimer 33rd Annual Healthcare Conference
08 Mar 2023 //
GLOBENEWSWIRE
Kineta to Host Key Opinion Leader Event on KVA12123
06 Mar 2023 //
GLOBENEWSWIRE
Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts
01 Mar 2023 //
GLOBENEWSWIRE
Kineta Completes Reverse Merger with Yumanity Therapeutics
19 Dec 2022 //
GLOBENEWSWIRE
Yumanity Declares Special Dividend In Connection with Proposed Asset Sale
05 Dec 2022 //
GLOBENEWSWIRE
Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program
01 Dec 2022 //
GLOBENEWSWIRE
Kineta to Participate in JMP Securities Hematology and Oncology Summit
29 Nov 2022 //
GLOBENEWSWIRE
Kineta Announces FDA Acceptance of Investigational NDA for KVA12123
15 Nov 2022 //
GLOBENEWSWIRE
Kineta to Present Pre-clinical Data on VISTA and CD27 Programs at SITC
27 Oct 2022 //
GLOBENEWSWIRE
Kineta Announces Clinical Collaboration with Merck to Evaluate KVA12123
17 Oct 2022 //
GLOBENEWSWIRE
Kineta to Present Anti-CD27 Agonist Preclinical Program at AACR Conference
13 Oct 2022 //
GLOBENEWSWIRE
Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4
29 Aug 2022 //
GLOBENEWSWIRE
Kineta Presented New Preclinical Data on its Anti-CD27 Agonist Ab Program
17 Dec 2021 //
PRNEWSWIRE
Kineta Presents Phase 1/2 Clinical Trial Design of KVA12.1 at the Society(SITC)
29 Nov 2021 //
PRNEWSWIRE
